Future therapeutic targets in osteoporosis

Current Opinion in Rheumatology

Volumn 21, Issue 4, 2009, Pages 380-385

  Deal, Chad ^a,b  

^a Orthopedic and Rheumatology Institute ^*  (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Calcium sensing receptor; Cathepsin K; Osteoporosis Wnt signaling; Sclerostin

Indexed keywords

ACE 011; ACTIVIN; ANABOLIC AGENT; BALICATIB; CALCIUM SENSING RECEPTOR; CATHEPSIN K; DENOSUMAB; DICKKOPF 1 PROTEIN; DICKKOPF 1 PROTEIN ANTIBODY; GLUCAGON LIKE PEPTIDE 2; ODANACATIB; PARATHYROID HORMONE; PLACEBO; RONACALERET; SCLEROSTIN; UNCLASSIFIED DRUG; WNT PROTEIN;

BONE DENSITY; BONE MASS; BONE TURNOVER; CELL FUNCTION; CLINICAL TRIAL; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SKIN MANIFESTATION;

ACTIVINS; ANABOLIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CATHEPSINS; GLUCAGON-LIKE PEPTIDE 2; HUMANS; OSTEOPOROSIS; RANK LIGAND; WNT PROTEINS;

EID: 67149126908     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32832cbc2a     Document Type: Review

References (32)

1. Kogianni G, Noble BS. The biology of osteocytes. Curr Osteoporos Rep 2007; 5:81-86. (Pubitemid 46954746)
2. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008; 118:421-428. An excellent review of the bone remodeling process including cytokines, cells, membrane proteins and signaling pathways involved in bone physiology. (Pubitemid 351206529)
3. McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005; 165:1762-1768. (Pubitemid 41138965)
4. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301. (Pubitemid 40463979)
5. Vahle JL, Long GG, Sandusky G, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 2002; 30:312-321.
6. McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003; 32:253-271.
7. Russell RG, Xia Z, Dunford JE, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007; 1117:209-257.
8. Del Fattore A, Peruzzi B, Rucci N, et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 2006; 43:315-325.
9. Henriksen DB, Alexandersen P, Hartmann B, et al. Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. Bone 2007; 40:723-729. (Pubitemid 46201945)
10. Henriksen DB, Alexandersen P, Hartmann B, Christiansen C. GLP-2 acutely uncouples bone resorption and bone formation in postmenopausal women. J Bone Miner Res 2008; 23:S474.
11. Henriksen DB, Alexandersen P, Hartmann B, et al. GLP-2 significantly increases hip BMD in postmenopausal women: a 120-day study. J Bone Miner Res 2007; 22 (Suppl 1):S37.
12. Vasiljeva O, Reinheckel T, Peters C, et al. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr Pharm Des 2007; 13:387-403.
13. Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther 2008; 83:172-176.
14. Gelb BD, Shi GP, Chapman HA, Desnick RJ. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996; 273:1236-1238.
15. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK- 0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008; 18:923-928. (Pubitemid 351179363)
16. Adami S, Supronik J, Hala T, et al. Effect of one year treatment with the cathepsin-K inhibitor, balicatib, on bone mineral density in postmenopausal women with osteopenia/osteoporosis. J Bone Miner Res 2006; 21 (Suppl 1): S24.
17. Itabashi A, Kurata N, Sugita Y, Kawai Y. Balicatib, a novel cathepsin-K inhibitor, increases intact PTH beyond diurnal patterns following 14-day administration in Japanese postmenopausal women. J Bone Miner Res 2006; 21 (Suppl 1):S24.
18. McClung M, Bone H, Cosman F, et al. A randomized, double-blind, placebo- controlled study of odanacatib (MK-822) in the treatment of postmenopausal women with low bone mineral density: 24-month results. J Bone Miner Res 2008; 23:S82.
19. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344:1434-1441.
20. Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007; 40:1434-1446. Details of the mechanism of action of PTH effect on osteoblasts including survival signals that delay apoptosis and increase cell number.
21. MacDonald B, Vittinghoff E, Cummings S, et al. An activecontrolled, non- inferiority study to compare the effect of ZT-031 with alendronate on the incidence of new vertebral fractures: the PACE (cyclic PTH and alendronate comparative efficacy) study. J Bone Miner Res 2008; 23:S460.
22. Okazaki M, Potts JT, Gardella TJ. Identification and optimization of residues in PTH and PTHrP that determine altered modes of binding to the PTH/PTHrP receptor. J Bone Miner Res 2008; 23:S103.
23. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem 2007; 45:139-167.
24. Glass DA 2nd, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology 2007; 148:2630-2634.
25. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116:1202-1209.
26. Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007; 148:2635-2643. (Pubitemid 46984775)
27. Gardner JC, van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis: affected individuals and gene carriers. J Clin Endocrinol Metab 2005; 90:6392-6395. (Pubitemid 41759290)
28. Padhi D, Stouch B, Fang L, et al. Antisclerostin antibody increases markers of bone formation in healthy postmenopausal women. J Bone Miner Metab 2007; 22 (Suppl 1):S37.
29. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocr Rev 2003; 24:218-235. (Pubitemid 36515285)
30. Billings PC, Fiori JL, Bentwood JL, et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressive (FOP). J Bone Miner Res 2008; 23:305-313. A study of a missense mutation in the activin receptor using the connective tissue dental progenitor cells. Reviews the effect on BMP signaling and osteogenic differentiation. (Pubitemid 351304661)
31. Fajardo RJ, Bouxsein ML, Pearsall AE, et al. ACE-011, a soluble activin receptor IIA fusion protein, increases BMD and improves microachitecture in cynomolgus monkeys. J Bone Miner Res 2007; 22:S65.
32. Ruckle J, Jacobs M, Kramer W, et al. A single dose of ACE-011 is associated with increases in bone formation and decreases in bone resorption markers in healthy postmenopausal women. J Bone Miner Res 2007; 22 (Suppl 1):S38.